Clinical manifestations and beta cell function in Swedish diabetic children have remained unchanged during the last 25 years

Diabetes/Metabolism Research and Reviews

Volumn 24, Issue 6, 2008, Pages 472-479

  Nordwall, Maria ^a   Ludvigsson, Johnny ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

Author keywords

C peptide; Children; Diabetes mellitus; Metabolic control; Partial remission; Type 1

Indexed keywords

C PEPTIDE; HEMOGLOBIN A1C; INSULIN;

ADOLESCENT; ARTICLE; CHILD; CLINICAL FEATURE; COHORT ANALYSIS; ENVIRONMENTAL FACTOR; FEMALE; HUMAN; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; ONSET AGE; PANCREAS ISLET BETA CELL; POPULATION RESEARCH; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN SECRETION; REMISSION; REPEATED DRUG DOSE; RETROSPECTIVE STUDY; SWEDEN; TREND STUDY;

ADOLESCENT; AGE OF ONSET; BODY MASS INDEX; C-PEPTIDE; CHILD; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; INSULIN; INSULIN-SECRETING CELLS; MALE; SWEDEN;

EID: 53349174600     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.871     Document Type: Article

References (46)

1. Pundziute-Lycka A, Dahlquist G, Urbonaite B, Zalinkevicius R. Time trend of childhood type 1 diabetes incidence in Lithuania and Sweden, 1983-2000. Acta Paediatr 2004; 93: 1519-1524.
2. Samuelsson U, Ludvigsson J, Bottazzo GF, et al. Indications for a more aggressive disease process in newly diagnosed insulin-dependent diabetic children in northern than in southern Europe. Acta Diabetol 1994; 31: 107-115.
3. Levy-Marchal C, Patterson CC, Green A. Geographical variation of presentation at diagnosis of type I diabetes in children: the EURODIAB study. European and Dibetes. Diabetologia 2001; 44(Suppl. 3): B75-B80.
4. Samuelsson U, Stenhammar L. Clinical characteristics at onset of Type 1 diabetes in children diagnosed between 1977 and 2001 in the south-east region of Sweden. Diabetes Res Clin Pract 2005; 68: 49-55.
5. The Diabetes Control and Complications Trial Research Group. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. Ann Intern Med 1998; 128: 517-523.
6. Ludvigsson J, Heding LG, Larsson Y, Leander E. C-peptide in juvenile diabetics beyond the postinitial remission period. Relation to clinical manifestations at onset of diabetes, remission and diabetic control. Acta Paediatr Scand 1977; 66: 177-184.
7. Mirouze J, Selam JL, Pham TC, Mendoza E, Orsetti A. Sustained insulin-induced remissions of juvenile diabetes by means of an external artificial pancreas. Diabetologia 1978; 14: 223-227.
8. Shah SC, Malone JI, Simpson NE. A randomized trial of intensive insulin therapy in newly diagnosed insulin-dependent diabetes mellitus. N Engl J Med 1989; 320: 550-554.
9. Flores d'Arcais A, Morandi F, Beccaria L, Meschi F, Chiumello G. Metabolic control in newly diagnosed type 1 diabetic children. Effect of continuous subcutaneous infusion. Horm Res 1984; 19: 65-69.
10. de Beaufort CE, Houtzagers CM, Bruining GJ, et al. Continuous subcutaneous insulin infusion (CSII) versus conventional injection therapy in newly diagnosed diabetic children: two-year follow-up of a randomized, prospective trial. Diabet Med 1989; 6: 766-771.
11. Edelmann E, Walter H, Biermann E, Schleicher E, Bachmann W, Mehnert H. Sustained normoglycemia and remission phase in newly diagnosed type I diabetic subjects. Comparison between continuous subcutaneous insulin infusion and conventional therapy during a one year follow-up. Horm Metab Res 1987; 19: 419-421.
12. Krarup T, Madsbad S. Effect of two periods with intensified insulin treatment on B-cell function during the first 18 months of type 1 (insulin-dependent) diabetes mellitus. Diabetes Metab 1986; 12: 256-260.
13. Perlman K, Ehrlich RM, Filler RM, Albisser AM. Sustained normoglycemia in newly diagnosed type I diabetic subjects. Short-term effects and one-year follow-up. Diabetes 1984; 33: 995-1001.
14. Schnell O, Eisfelder B, Standl E, Ziegler AG. High-dose intravenous insulin infusion versus intensive insulin treatment in newly diagnosed IDDM. Diabetes 1997; 46: 1607-1611.
15. Ludvigsson J, Heding L, Lieden G, Marner B, Lemmark A. Plasmapheresis in the initial treatment of insulin-dependent diabetes mellitus in children. Br Med J (Clin Res Ed) 1983; 286: 176-178.
16. Ludvigsson J, Samuelsson U, Johansson C, Stenhammar L. Treatment with antioxidants at onset of type 1 diabetes in children: a randomized, double-blind placebo-controlled study. Diabetes Metab Res Rev 2001; 17: 131-136.
17. Ludvigsson J, Samuelsson U, Ernerudh J, Johansson C, Stenhammar L, Berlin G. Photopheresis at onset of type 1 diabetes: a randomised, double blind, placebo controlled trial. Arch Dis Child 2001; 85: 149-154.
18. Ortqvist E, Bjork E, Wallensteen M, et al. Temporary preservation of beta-cell function by diazoxide treatment in childhood type 1 diabetes. Diabetes Care 2004; 27: 2191-2197.
19. Cole TJ, Bellizzi MC, Flegal KM, Dietz WH. Establishing a standard definition for child overweight and obesity worldwide: international survey. BMJ 2000; 320: 1240-1243.
20. Bidwell JL, Bidwell EA, Savage DA, Middleton D, Klouda PT, Bradley BA. A DNA-RFLP typing system that positively identifies serologically well-defined and ill-defined HLA-DR and DQ alleles, including DRw10. Transplantation 1988; 45: 640-646.
21. Olerup O, Zetterquist H. HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 1992; 39: 225-235.
22. Matthews JN, Altman DG, Campbell MJ, Royston P. Analysis of serial measurements in medical research. BMJ 1990; 300: 230-235.
23. Kullberg CE, Bergstrom A, Dinesen B, et al. Comparisons of studies on diabetic complications hampered by differences in GHb measurements. Diabetes Care 1996; 19: 726-729.
24. Heding LG. Radioimmunological determination of human C-peptide in serum. Diabetologia 1975; 11: 541-548.
25. Couper JJ, Hudson I, Werther GA, Warne GL, Court JM, Harrison LC. Factors predicting residual beta-cell function in the first year after diagnosis of childhood type 1 diabetes. Diabetes Res Clin Pract 1991; 11: 9-16.
26. Levy-Marchal C, Papoz L, de Beaufort C, et al. Clinical and laboratory features of type 1 diabetic children at the time of diagnosis. Diabet Med 1992; 9: 279-284.
27. Pinkey JH, Bingley PJ, Sawtell PA, Dunger DB, Gale EA, The Bart's-Oxford Study Group. Presentation and progress of childhood diabetes mellitus: a prospective population-based study. Diabetologia 1994; 37: 70-74.
28. Komulainen J, Lounamaa R, Knip M, Kaprio EA, Akerblom HK, Childhood Diabetes in Finland Study Group. Ketoacidosis at the diagnosis of type 1 (insulin dependent) diabetes mellitus is related to poor residual beta cell function. Arch Dis Child 1996; 75: 410-415.
29. Ortqvist E, Falorni A, Scheynius A, Persson B, Lernmark A. Age governs gender-dependent islet cell autoreactivity and predicts the clinical course in childhood IDDM. Acta Paediatr 1997; 86: 1166-1171.
30. Bober E, Dundar B, Buyukgebiz A. Partial remission phase and metabolic control in type 1 diabetes mellitus in children and adolescents. J Pediatr Endocrinol Metab 2001; 14: 435-441.
31. Knip M, Sakkinen A, Huttunen NP, et al. Postinitial remission in diabetic children-an analysis of 178 cases. Acta Paediatr Scand 1982; 71: 901-908.
32. Kordonouri O, Danne T, Enders I, Weber B. Does the long-term clinical course of type I diabetes mellitus differ in patients with prepubertal and pubertal onset? Results of the Berlin Retinopathy Study. Eur J Pediatr 1998; 157: 202-207.
33. Lombardo F, Valenzise M, Wasniewska M, et al. Two-year prospective evaluation of the factors affecting honeymoon frequency and duration in children with insulin dependent diabetes mellitus: the key-role of age at diagnosis. Diabetes Nutr Metab 2002; 15: 246-251.
34. Wallensteen M, Dahlquist G, Persson B, et al. Factors influencing the magnitude, duration, and rate of fall of B-cell function in type 1 (insulin-dependent) diabetic children followed for two years from their clinical diagnosis. Diabetologia 1988; 31: 664-669.
35. Schiffrin A, Suissa S, Weitzner G, Poussier P, Lalla D. Factors predicting course of beta-cell function in IDDM. Diabetes Care 1992; 15: 997-1001.
36. Sochett EB, Daneman D, Clarson C, Ehrlich RM. Factors affecting and patterns of residual insulin secretion during the first year of type 1 (insulin-dependent) diabetes mellitus in children. Diabetologia 1987; 30: 453-459.
37. Salardi S, Zucchini S, Cicognani A, et al. The severity of clinical presentation of type 1 diabetes in children does not significantly influence the pattern of residual beta-cell function and long-term metabolic control. Pediatr Diabetes 2003; 4: 4-9.
38. Gjessing HJ, Matzen LE, Froland A, Faber OK. Correlations between fasting plasma C-peptide, glucagon-stimulated plasma C-peptide, and urinary C-peptide in insulin-treated diabetics. Diabetes Care 1987; 10: 487-490.
39. Sjoberg S, Gunnarsson R, Ostman J. Residual C-peptide production in type I diabetes mellitus. A comparison of different methods of assessment and influence on glucose control. Acta Med Scand 1983; 214: 231-237.
40. Escobar-Jimenez F, Herrera Pombo JL, Gomez-Villalba R, Nunez del Carril J, Aguilar M, Rovira A. Standard breakfast test: an alternative to glucagon testing for C-peptide reserve? Horm Metab Res 1990; 22: 339-341.
41. Clarson C, Daneman D, Drash AL, Becker DJ, Ehrlich RM. Residual beta-cell function in children with IDDM: reproducibility of testing and factors influencing insulin secretory reserve. Diabetes Care 1987; 10: 33-38.
42. Rjasanowski I, Michaelis D, Keilacker H, Besch W, Richter KV, Heinke P. 5-year follow-up study of C-peptide secretion in newly diagnosed type I diabetics: relations to HLA-phenotype, insulin requirement and metabolic control. Exp Clin Endocrinol 1987; 89: 216-224.
43. Dahlquist G, Blom L, Persson B, Wallensteen M, Wall S. The epidemiology of lost residual beta-cell function in short term diabetic children. Acta Paediatr Scand 1988; 77: 852-859.
44. Madsbad S, Faber OK, Binder C, McNair P, Christiansen C, Transbol I. Prevalence of residual beta-cell function in insulin-dependent diabetics in relation to age at onset and duration of diabetes. Diabetes 1978; 27: 262-264.
45. Scholin A, Bjorklund L, Borg H, et al. Islet antibodies and remaining beta-cell function 8 years after diagnosis of diabetes in young adults: a prospective follow-up of the nationwide Diabetes Incidence Study in Sweden. J Intern Med 2004; 255: 384-391.
46. Holl RW, Swift PG, Mortensen HB, et al. Insulin injection regimens and metabolic control in an international survey of adolescents with type 1 diabetes over 3 years: results from the Hvidore study group. Eur J Pediatr 2003; 162: 22-29.